Intellia Reports Phase 3 HAELO Trial Met Key Secondary Endpoints; BLA Response Expected In H1 2027
Intellia Therapeutics said Phase 3 HAELO trial results for Lonvo-z (lonvoguran ziclumeran) met key secondary endpoints in hereditary angioedema. The company reported 89% fewer patients needing on-demand treatment, 91% mean reduction in moderate/severe attacks, and a 17.04-point AE-QoL improvement. It also cited generally mild adverse events. A rolling BLA began April 2026; FDA response expected H1 2027.
Positive Phase 3 secondary endpoint readout and FDA BLA initiation increase probability of regulatory progress and potential 1H 2027 launch.
Intellia reported Phase 3 HAELO trial met key secondary endpoints for Lonvo-z and initiated rolling BLA submission for FDA review.
Near-term upside bias as traders price higher likelihood of approval; volatility likely around FDA review milestones.
Background
HAELO is Intellia’s Phase 3 trial for Lonvo-z (lonvoguran ziclumeran), an in vivo CRISPR gene-editing candidate targeting kallikrein B1 to reduce attacks.
Why it matters
The article adds secondary endpoint results (on-demand treatment reduction, moderate/severe attack reduction, AE-QoL improvement) and states rolling BLA submission was initiated in April 2026, with expected approval and U.S. launch in 1H 2027.
Market relevance
Traders get incremental Phase 3 efficacy confirmation plus a concrete regulatory step (rolling BLA initiation) that can re-rate approval odds and the launch timeline.
Market effects
Reinforces investor confidence in in vivo CRISPR gene-editing approaches for rare diseases and kallikrein inhibition strategy.
European conference presentation may support sentiment among EU-focused biotech investors.
Could modestly lift global rare-disease/HAE treatment sentiment and competitive read-through for kallikrein-targeting therapies.
Alternative perspectives
Secondary endpoints confirmation may already be partially anticipated after the primary endpoint report; market may demand clearer magnitude vs placebo or additional durability data.
FDA review timing and potential CMC/labeling questions for rolling BLA could dominate price action more than incremental endpoint details.
Key entities
- companyIntellia Therapeutics Inc.
Sponsor of the Phase 3 HAELO trial for Lonvo-z; initiated rolling BLA submission and expects U.S. launch in 1H 2027.
- drug_candidateLonvo-z (lonvoguran ziclumeran)
In vivo CRISPR gene-editing candidate intended to permanently lower kallikrein protein levels for hereditary angioedema prevention.
- regulatorFDA
Receives the rolling BLA submission for Lonvo-z; approval timing cited as 1H 2027.
